Danel (Adir Yeoshua) Ltd (DANE) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Danel (Adir Yeoshua) Ltd stock ILS 412, price ILS 397, upside +3.7%, quality 66 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range 198.37 ILS – 670.58 ILS · fair‑value band 289.73 ILS – 514.71 ILS · the 396.90 ILS price screens below the 411.77 ILS fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Danel (Adir Yeoshua) in your weekly email
Every Wednesday you see whether Danel (Adir Yeoshua) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Danel (Adir Yeoshua) Ltd provides human resources services in Israel.
Show moreShow less
The company provides recruitment, placement, and employment services in the areas of finance, insurance, administration, senior management, high-tech, biotech, cleantech, as well as outsourcing project management services, technological employee employment services, and occupational and computerized diagnostic services; payroll services; and nursing and medical services to disabled seniors, ministry of defense beneficiaries, and others.
It also manages and operates dormitories and hostels, schools, rehabilitation and therapeutic day centers; and provides Referrals to special schools for complex populations, such as multisystemic learning disabilities, moderate-low functioning autism, intellectual disabilities, mental/emotional difficulties, and behavioral disorders.
In addition, the company provides medical services, including surgical activities in ophthalmology field. Danel (Adir Yeoshua) Ltd was incorporated in 1974 and is based in Ramat Gan, Israel.
Stock analysis
Danel (Adir Yeoshua) Ltd (DANE) currently trades at 396.90 ILS, while our model-based Fair Value estimate is 411.77 ILS, so the stock looks roughly fairly valued today (gap 3.6%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 479.54 ILS per share, and 14 of the 26 models we run sit above the 396.90 ILS price.
Bear case: the Dividend Discount group reads lowest at 169.82 ILS, and 12 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 289.73 ILS (bear) to 514.71 ILS (bull), the price of 396.90 ILS sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Danel (Adir Yeoshua) Ltd reported revenue of 2.9B ILS in FY2025 versus 2.3B ILS in FY2021, a compound +6.1%/yr. Reported net income was 117M ILS in FY2025, compounding −9.5%/yr from FY2021.
Key figures
Market cap 2.4B ILS Small · P/E ratio 15.1 · P/S ratio 0.80 · EPS (TTM) 26.22 ILS · Dividend yield 5.6% · Net margin 4.4% · Return on equity 28.2% · Return on assets (EBIT) 13.3% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 4%, DANE screens cheaper than that median.
Fair Value models
Bear289.73 ILSFair Value 411.77 ILSBull514.71 ILS
Price 396.90 ILS · Upside +3.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (3.54 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2020 (pandemic). Over 10 years: +10.4% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +5.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.2%
Dividend (yield on the price)5.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.5% vs 5.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 7%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 63% above its own trend.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+9.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +7.0% a year for the price.
Compare Danel (Adir Yeoshua) Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Top 25%
Fair Value upside+3.7% · Above median
Profitability
Return on equity (12 months)28.2% · Top 25%
Return on assets8.2% · Top 25%
Net margin (12 months)4.4% · Below median
Operating margin (12 months)6.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)6.7% · Above median
Dividend yield (12 months)5.6% · Top 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)15.1× · Cheaper than median
P/B4.66× · Priciest 25%
P/S (12 months)0.80× · Cheapest 25%
Price / free cash flow (fiscal year)16.6× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Danel (Adir Yeoshua) Ltd (DANE) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of 411.77 ILS versus a price of 396.90 ILS, about +4% upside (fairly valued).
What is the fair value of DANE?
Our model-based fair value for Danel (Adir Yeoshua) Ltd is 411.77 ILS (as of Nov 5, 2026), built from audited fundamentals. The current price: 396.90 ILS.
What is the quality score of DANE?
Danel (Adir Yeoshua) Ltd has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Danel (Adir Yeoshua) Ltd (DANE)?
Our model-based price target is the fair value of 411.77 ILS (as of Nov 5, 2026) from 26 valuation models. Cautious scenario 289.73 ILS, optimistic scenario 514.71 ILS. It is a calculation from audited fundamentals, not an analyst target.
What is the Danel (Adir Yeoshua) Ltd stock forecast for 2026?
Our models put fair value at 411.77 ILS, about +4% upside versus a price of 396.90 ILS (fairly valued). Cautious scenario 289.73 ILS, optimistic scenario 514.71 ILS. The calculation is refreshed regularly with new filings.
What is the revenue of Danel (Adir Yeoshua) Ltd (DANE)?
Danel (Adir Yeoshua) Ltd reported trailing-twelve-month revenue of about 3.0B ILS (latest available figure, as of Nov 5, 2026).
Does Danel (Adir Yeoshua) Ltd pay a dividend?
Danel (Adir Yeoshua) Ltd currently shows a dividend yield of 5.57% relative to its recent price (as of Nov 5, 2026).
How much is the dividend of Danel (Adir Yeoshua) Ltd (DANE) and when is the ex-dividend date?
Danel (Adir Yeoshua) Ltd pays a dividend of 22.09 ILS per share a year, a dividend yield of 5.6%. The last ex-dividend date was Aug 25, 2026. A dividend has been paid every year since at least 2003. The payout ratio is 84.3% of earnings. Free cash flow covers the dividend 1.09 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Danel (Adir Yeoshua) Ltd (DANE)?
For today's price to be fair in a discounted-cash-flow model, Danel (Adir Yeoshua) Ltd would have to grow free cash flow by +9.2 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.9 % per year. As of Nov 5, 2026.
What discount rate (WACC) does the fair value of DANE use?
Our models discount Danel (Adir Yeoshua) Ltd at 11.6 %: a base by market capitalisation (small), damped by beta 0.02, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Danel (Adir Yeoshua) Ltd that is +9.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Danel (Adir Yeoshua) Ltd (DANE) delivered so far?
Over the past 5 years revenue at Danel (Adir Yeoshua) Ltd grew +7.9 % a year. The price currently implies free-cash-flow growth of +9.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Danel (Adir Yeoshua) Ltd (DANE) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Danel (Adir Yeoshua) Ltd (+9.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Danel (Adir Yeoshua) Ltd (DANE)?
The free-cash-flow yield on the price is 6.04 %: that much free cash flow Danel (Adir Yeoshua) Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Danel (Adir Yeoshua) Ltd (DANE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Danel (Adir Yeoshua) Ltd it is 411.77 ILS per share (as of Nov 5, 2026), against a price of 396.90 ILS. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Danel (Adir Yeoshua) Ltd stock overvalued or undervalued in 2026?
As of Nov 5, 2026, DANE trades below its calculated fair value: price 396.90 ILS, fair value 411.77 ILS, a gap of about +4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DANE?
No. The price is what the market pays today (396.90 ILS); the fair value is what the company's own numbers justify (411.77 ILS). For Danel (Adir Yeoshua) Ltd the two are 14.87 ILS per share apart. That gap is exactly why we show both numbers side by side.
How much is Danel (Adir Yeoshua) Ltd worth?
The market values Danel (Adir Yeoshua) Ltd at about 2.4B ILS (market capitalisation, as of Nov 5, 2026). Per share that is 396.90 ILS; our models calculate a fair value of 411.77 ILS per share.
What do the bullish and bearish scenarios say about DANE?
Our models span a range for Danel (Adir Yeoshua) Ltd: cautious scenario 289.73 ILS, base 411.77 ILS, optimistic 514.71 ILS per share (as of Nov 5, 2026, price 396.90 ILS). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DANE?
Danel (Adir Yeoshua) Ltd trades at a price-to-earnings ratio of 15.1 (as of Nov 5, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 411.77 ILS is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 21.0. Other multiples: P/B 4.7, P/S 0.8, EV/EBITDA 8.8.
How solid is the balance sheet of Danel (Adir Yeoshua) Ltd (DANE)?
Balance-sheet figures for Danel (Adir Yeoshua) Ltd (as of Nov 5, 2026): return on equity 28.2%, debt of 0.07 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is DANE from its 52-week high?
Danel (Adir Yeoshua) Ltd trades at 396.90 ILS, about 18% below its 52-week high of 484.33 ILS and 4% above the low of 381.80 ILS (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 411.77 ILS is for.
Which stocks are comparable to Danel (Adir Yeoshua) Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Danel (Adir Yeoshua) Ltd stock attractive at the current price?
The data as of Nov 5, 2026: price 396.90 ILS, calculated fair value 411.77 ILS (+4%), Quality Score 66/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DANE calculated?
We run Danel (Adir Yeoshua) Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 411.77 ILS builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Danel (Adir Yeoshua) Ltd currently trades 4% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Danel (Adir Yeoshua) Ltd (DANE)?
The closing price on Nov 6, 2026 was 396.90 ILS. Our model-based fair value is 411.77 ILS, about +4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Danel (Adir Yeoshua) Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Danel (Adir Yeoshua) Ltd (DANE) come from?
Earnings per share at Danel (Adir Yeoshua) Ltd grew +0.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.0 %, EBIT margin +0.2 %, tax rate −2.5 %, residual (interest, one-offs) −5.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Danel (Adir Yeoshua) Ltd
How large is the market capitalisation of Danel (Adir Yeoshua) Ltd (DANE)?
The market capitalisation of Danel (Adir Yeoshua) Ltd is 2.4B ILS. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Danel (Adir Yeoshua) Ltd (DANE)?
The price-to-sales ratio of Danel (Adir Yeoshua) Ltd is 0.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Danel (Adir Yeoshua) Ltd (DANE)?
Earnings per share at Danel (Adir Yeoshua) Ltd are 26.22 ILS (price ÷ EPS = P/E 15.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Danel (Adir Yeoshua) Ltd (DANE)?
The dividend yield of Danel (Adir Yeoshua) Ltd is 5.6% (payout 84.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Danel (Adir Yeoshua) Ltd (DANE)?
The net margin of Danel (Adir Yeoshua) Ltd is 4.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Danel (Adir Yeoshua) Ltd (DANE)?
The return on equity (ROE) of Danel (Adir Yeoshua) Ltd is 28.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Danel (Adir Yeoshua) Ltd (DANE)?
On an EBIT basis the return on assets of Danel (Adir Yeoshua) Ltd is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Danel (Adir Yeoshua) Ltd (DANE)?
The operating margin of Danel (Adir Yeoshua) Ltd is 6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Danel (Adir Yeoshua) Ltd (DANE)?
Revenue at Danel (Adir Yeoshua) Ltd is growing +6.7% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Danel (Adir Yeoshua) Ltd (DANE)?
Earnings per share at Danel (Adir Yeoshua) Ltd are growing +13.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Danel (Adir Yeoshua) Ltd (DANE) carry?
The net debt of Danel (Adir Yeoshua) Ltd is 113M ILS (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Danel (Adir Yeoshua) Ltd in the live analysis
One click puts Danel (Adir Yeoshua) Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 5, 2026